Replies to post #4825 on OncoSec Medical Inc (ONCSQ)

[trading.jeff]

$INO PR and its relevance to $ONCS:

Roche and Inovio Pharmaceuticals partner on Inovio's prostate cancer and hepatitis B immunotherapy products

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that they have entered into an exclusive worldwide license agreement to research, develop and commercialize Inovio's highly-optimized, multi-antigen DNA immunotherapies targeting prostate cancer and hepatitis B.

The complete PR can be found by clicking this link:

http://ih.advfn.com/p.php?pid=nmona&article=59139327

[lasers]

Strange as it is, OncoSec is far more advanced than Inovio when it comes to clinical trials for cancer treatment with both its NeoPulse and ImmunoPulse. The Inovio-Roche deal is primarily for R&D. OncoSec Bleomycin has been Commercially approved by the EMA throughout Europe. It has successfully been approved to be equal to surgery for Breast Cancer. This would also mean Prostate Cancer. There would be no need for surgical removal.

Yes what is good for Inovio is good for OncoSec. They do cross-license their Patented Electroporation devices.